Genoscience Pharma
Marseille, FR· latest recorded location
GENOSCIENCE PHARMA is named on 6 US grants and 7 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 6
- Published applications
- 7
- Inventors
- 13
- Granted in 2026 so far
- 0
- Most recent grant
- 1 Mar 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2013 | 1 | 2 |
| 2014 | 0 | 0 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 1 | 2 |
| 2020 | 2 | 1 |
| 2021 | 0 | 0 |
| 2022 | 1 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Technology areas
Share of 13 documents
Recent patents
- Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases1 Mar 2022US 11,261,189 B2
- Substituted 2,4 diamino-quinoline as new anticancer agents28 Jul 2020US 10,722,505 B2
- Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases3 Mar 2020US 10,577,362 B2
- Quinolines derivatives as novel anticancer agents15 Jan 2019US 10,179,770 B2
- Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent24 Mar 2015US 8,987,302 B2
- Crystalline freebase form of 2-(4-chlorobenzylamino)-4-(4-tert-butylaminopiperidin-1-yl)-quinoline and uses thereof6 Mar 2025US 2025/0074885 A1
- Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases12 Mar 2020US 2020/0079781 A1
- Substituted 2,4 diamino-quinoline as new anticancer agents17 Oct 2019US 2019/0314359 A1
- Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases16 May 2019US 2019/0144437 A1
- Quinolines derivatives as novel anticancer agents29 Sep 2016US 2016/0280653 A1
Most cited
By later US patents